Skip to main content
OpenTrials
Completed

NCT Number: NCT02087800

Smoking, Stress & Allopregnanolone Response

This study aims to characterize the effect of smoking on stress-induced allopregnanolone (ALLO) response in women by menstrual phase. The investigators hypothesize that women who smoke will have a blunted ALLO response to stress.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–40 year

Sex eligibility

Female

Study type

Observational

Primary location

University of Minnesota Tobacco Research Program

Minneapolis, Minnesota, 55455, United States

About this study

Cigarette smoking persists as the leading cause of preventable morbidity and mortality. Thus, finding ways to maximize quitting behavior is critical. Women have a more difficult time achieving smoking abstinence than men. The risk for smoking relapse appears to vary by menstrual phase such that the follicular phase is associated with greater risk compared to the luteal phase. Women are also more likely to smoke in response to stressful stimuli than men. Allopregnanolone (ALLO) is a stress-reducing neuroactive steroid that is primarily metabolized from the sex hormone progesterone and, therefore, varies by menstrual phase in women. Recent preclinical literature has indicated that ALLO may protect against drug abuse behaviors. Unfortunately, ALLO remains largely unexplored in clinical samples containing women.

In this study we aim to characterize the effect of smoking on stress-induced ALLO response in women by menstrual phase. To achieve this goal, we will recruit a sample of premenopausal women who smoke (n=30) and do not smoke (n=30) to participate in a controlled cross-over study. All participants will complete two four-hour lab sessions timed to occur in the Follicular (F; low ALLO) and Luteal (L; high ALLO) menstrual phases. Each lab session will contain an acute stressor along with a timed series of assessments including blood samples (for ALLO measurement) and self-report of mood and perceived stress.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female between the ages of 18-40 years old
  • Stable physical/mental health,
  • Self-report of regular menstrual cycles,
  • Self-report of either smoking either current or never smoking,
  • English fluency,
  • Ability to provide informed consent

Exclusion criteria

  • Self-report of current use of illicit drugs, other tobacco products, nicotine, or smoking cessation medications,
  • Current or recent pregnancy or breastfeeding,
  • Current or recent use of exogenous hormones (including birth control pills),
  • Current or recent use of psychotropic medications.

Treatment and study plan

F phase lab session

Behavioral

F phase sessions will occur three to seven days post the onset of menses. It will include blood draws, an acute stressor and completion of questionnaires.

L phase lab session

Behavioral

L phase sessions will occur six to ten days prior to the onset of the next expected menses. It will include blood draws, an acute stressor and completion of questionnaires.

Primary outcomes

  1. Change in allopregnanolone levels

    Time frame: 6 weeks

    The change in ALLO after delivery of the acute stressor will be analyzed.

Secondary outcomes

  1. Change in mood

    Time frame: 6 weeks

    We will analyze ALLO levels and mood to see if there is an association between the two.

  2. Change in stress level

    Time frame: 6 weeks

    We will analyze ALLO levels and perceived stress level to see if there is an association and whether stress changes as ALLO levels change.

Sponsors and collaborators

Lead sponsor

University of Minnesota

Other

Registry information

Official study title

Effect of Smoking on Stress-Induced Allopregnanolone Response in Women by Menstrual Phase

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Mar 14, 2014
Registry last updated
Nov 30, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.